IBRX vs IMVT: stock comparison and AI forecast
Immunitybio, Inc. (IBRX) and Immunovant, Inc. (IMVT) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
IBRX Immunitybio, Inc.
- Price
- $8.93 +6.6% · 6M
- Market Cap
- $8.49B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
IMVT Immunovant, Inc.
- Price
- $29.90 +4.3% · 6M
- Market Cap
- $5.86B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- IBRX is 1.4 times larger than IMVT by market capitalization ($8.49B against $5.86B).
- Over the last six months IBRX returned +6.6% and IMVT +4.3%.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | IBRX | IMVT |
|---|---|---|
| Market Cap | $8.49B | $5.86B |
| P/B Ratio | – | 7.97x |
| EPS | $-0.50 | $-2.81 |
| Book Value/Share | – | $3.56 |
| Revenue/Share | $0.16 | – |
| FCF/Share | $-0.27 | – |
Profitability & Margins
| Metric | IBRX | IMVT |
|---|---|---|
| ROE | – | -73.2% |
| ROA | – | -63.1% |
| ROIC | -45.6% | – |
| Gross Margin | 99.3% | – |
| Operating Margin | -151.9% | – |
| EBT Margin | -598.7% | – |
| Tax Rate | 0.0% | 0.1% |
Financial Health
| Metric | IBRX | IMVT |
|---|---|---|
| Current Ratio | 5.72x | 7.27x |
| Quick Ratio | 5.70x | – |
| D/E Ratio | – | 0.16x |
| Financial Leverage | – | 1.16x |
| Interest Coverage | -3.1x | – |
| Working Capital | $362M | $734M |
Cash Flow
| Metric | IBRX | IMVT |
|---|---|---|
| Operating Cash Flow | -$281M | -$414M |
| Free Cash Flow | -$288M | – |
| Capital Spending | -$7M | – |
| FCF/Sales | -173.8% | – |
| CapEx/Sales | 4.2% | – |
Operational Efficiency
| Metric | IBRX | IMVT |
|---|---|---|
| Asset Turnover | 0.26x | – |
| Receivables Turnover | 3.1x | – |
| Inventory Turnover | 0.6x | – |
| Fixed Assets Turnover | 1.4x | – |
| Days Sales Outstanding | 118 days | – |
| Days Inventory | 647 days | – |
| Payables Period | 18557 days | – |
| Cash Conversion Cycle | -17793 days | – |
Income Statement
| Metric | IBRX | IMVT |
|---|---|---|
| Total Revenue | $166M | – |
| Operating Income | -$252M | – |
| Net Income | – | -$538M |
| R&D Expense | – | $498M |
| Cost of Goods Sold | $1M | – |
Dividend & Shareholder Information
| Metric | IBRX | IMVT |
|---|---|---|
| Shares Outstanding | 1060M | 207M |
IBRX vs IMVT: stock comparison and AI forecast
Which is bigger, IBRX or IMVT?
IBRX is 1.4 times larger than IMVT by market capitalization ($8.49B against $5.86B).
Which stock performed better over the last six months, IBRX or IMVT?
Over the last six months IBRX returned +6.6% and IMVT +4.3%.
Which one does Intratio's AI model rank higher, IBRX or IMVT?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.